文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

麻疹暴发作为治理失败的信号:孟加拉国2026年免疫崩溃的教训

Measles outbreaks as signals of governance failure: Lessons from Bangladesh's 2026 immunisation collapse.
PubMed 文献 · Vaccine · 2026-07-15

孟加拉国2026年麻疹暴发前,麻疹-风疹疫苗接种覆盖率在一个规划周期内从95%以上骤降至约57%,此前十余年保持稳定高位。本文评论认为此次崩溃反映2025年卫生部门重组导致的机构中断,而非需求侧失败或疫苗犹豫。行政重组削弱问责、扰乱物流并取消补种活动,常规监测因覆盖率数据未与预设阈值或可执行响应协议挂钩而未能防止崩溃。

要点

  • 免疫规划连续性依赖治理安排,机构重组可迅速瓦解高覆盖率。
  • 覆盖率数据需与预设阈值和可执行响应协议联动以预防崩溃。
  • 当需求侧失败证据不足时,麻疹复燃应触发治理与问责系统审查。

核心结论

  • 孟加拉国2026年麻疹暴发源于治理失败而非需求侧问题。
  • 免疫规划作为机构职能,其连续性取决于治理安排。

研究设计与样本

  • 本文为评论文章,基于孟加拉国2026年麻疹暴发及免疫规划覆盖率变化进行政策分析。

主要发现

  • 麻疹-风疹疫苗接种覆盖率在一个规划周期内从95%以上降至约57%,此前十余年稳定高位。
  • 2025年卫生部门重组削弱问责、扰乱物流并取消计划补种活动。
  • 常规监测因覆盖率数据未与预设阈值或可执行响应协议挂钩而未能防止崩溃。

临床怎么用

  • 应系统审查免疫规划的治理与问责机制以预防覆盖率崩溃。
  • 将覆盖率数据与预设阈值和可执行响应协议挂钩以强化监测预警。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bangladesh's 2026 measles outbreak followed an abrupt decline in measles-rubella vaccination coverage-from above 95% to approximately 57% within a single programme cycle-after more than a decade of stable high performance. This commentary argues that the collapse reflects institutional disruption linked to health sector restructuring in 2025, rather than demand side failure or vaccine hesitancy. Administrative reorganisation weakened accountability, disrupted logistics, and led to the cancellation of planned catch up activities, removing key compensatory mechanisms at a critical moment. Routine monitoring failed to prevent collapse because coverage data were not linked to predefined thresholds or enforceable response protocols. The Bangladesh case highlights a broader policy lesson: immunisation programmes are institutional functions whose continuity depends on governance arrangements. Where demand side failure is unsupported, measles resurgences should prompt systematic review of governance and accountability.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jahan Y, Aziz AB. Measles outbreaks as signals of governance failure: Lessons from Bangladesh's 2026 immunisation collapse. Vaccine. 2026. PMID: 42456565. doi:10.1016/j.vaccine.2026.128924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。